TY - JOUR
T1 - Significance of Lgr5+ve cancer stem cells in the colon and rectum
AU - Takahashi, Hidekazu
AU - Ishii, Hideshi
AU - Nishida, Naohiro
AU - Takemasa, Ichiro
AU - Mizushima, Tsunekazu
AU - Ikeda, Masataka
AU - Yokobori, Takehiko
AU - Mimori, Koshi
AU - Yamamoto, Hirofumi
AU - Sekimoto, Mitsugu
AU - Doki, Yuichiro
AU - Mori, Masaki
N1 - Funding Information:
ACKNOWLEDGMENT This work was supported in part by a grant-in-aid for scientific research on Priority Areas (20012039), a grant-in-aid for scientific research (S, 21229015; C, 20590313), and a grant-in-aid for Young Scientists (B, 21791287) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
PY - 2011/4
Y1 - 2011/4
N2 - Purpose: Although recent studies show that leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5)+ve cells targeted by Wnt drive self-renewal in the skin and gastrointestinal organs, the clinicopathological significance of Lgr5+ve cancer stem cells (CSCs) of the colon remains to be elucidated. Experimental Design. We studied the Wnt-targeted Lgr5 pathway in colorectal cancer (CRC). The expression of LGR5, c-MYC, p21CIP1/WAF1/CDKN1A, glutaminase (GLS), and miRs-23a and -23b (that target LGR5 and GLS) was evaluated by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR). The Lgr5 protein was evaluated by immunohistochemistry. The clinical relevance of gene expression in terms of patient survival was also evaluated. Results: Overexpression of LGR5 was significantly associated with expression of c-MYC, p21CIP1/WAF1/ CDKN1A, and GLS (p<0.0001), and inversely associated with miR-23a/b (p<0.05). Immunohistochemical analysis indicated that Lgr5 may be embedded in benign adenomas, localized at the tumor-host interface, and detectable over a broad area in established tumors. High level of LGR5 expression was associated with poor prognosis for CRC cancer patients (disease-free survival; p<0.05). Conclusions: This study supports a significant role for LGR5 in the CSC hypothesis in CRC: (1) Lgr5+ve CSCs, presumably derived from normal stem cells in colonic crypts, proliferate, and the gene is overexpressed during CRC development; (2) LGR5 expression is associated with activation of Wnt pathway, including oncogenic c-MYC and high energy production via glutaminolysis; (3) LGR5 expression may be a poor prognostic factor for CRC patients. Further study of LGR5 should contribute to the development of CSC-based cancer therapeutics.
AB - Purpose: Although recent studies show that leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5)+ve cells targeted by Wnt drive self-renewal in the skin and gastrointestinal organs, the clinicopathological significance of Lgr5+ve cancer stem cells (CSCs) of the colon remains to be elucidated. Experimental Design. We studied the Wnt-targeted Lgr5 pathway in colorectal cancer (CRC). The expression of LGR5, c-MYC, p21CIP1/WAF1/CDKN1A, glutaminase (GLS), and miRs-23a and -23b (that target LGR5 and GLS) was evaluated by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR). The Lgr5 protein was evaluated by immunohistochemistry. The clinical relevance of gene expression in terms of patient survival was also evaluated. Results: Overexpression of LGR5 was significantly associated with expression of c-MYC, p21CIP1/WAF1/ CDKN1A, and GLS (p<0.0001), and inversely associated with miR-23a/b (p<0.05). Immunohistochemical analysis indicated that Lgr5 may be embedded in benign adenomas, localized at the tumor-host interface, and detectable over a broad area in established tumors. High level of LGR5 expression was associated with poor prognosis for CRC cancer patients (disease-free survival; p<0.05). Conclusions: This study supports a significant role for LGR5 in the CSC hypothesis in CRC: (1) Lgr5+ve CSCs, presumably derived from normal stem cells in colonic crypts, proliferate, and the gene is overexpressed during CRC development; (2) LGR5 expression is associated with activation of Wnt pathway, including oncogenic c-MYC and high energy production via glutaminolysis; (3) LGR5 expression may be a poor prognostic factor for CRC patients. Further study of LGR5 should contribute to the development of CSC-based cancer therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=79955800644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955800644&partnerID=8YFLogxK
U2 - 10.1245/s10434-010-1373-9
DO - 10.1245/s10434-010-1373-9
M3 - Article
C2 - 21125339
AN - SCOPUS:79955800644
SN - 1068-9265
VL - 18
SP - 1166
EP - 1174
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 4
ER -